Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by OysterBuctoucheon Jan 13, 2020 9:01am
117 Views
Post# 30545605

Been there ...done it..

Been there ...done it..Beenthere,

You obviously dont like JD. Your posts are either name calling JD -or mocking him for what he has to say about the science or assets of BTI. Fact-all shareholders are frustrated with share price. And correct -we all commiserate over why ? But we all know we are severely under funded which inhibits are ability to advance. We are also in an extremely complex space. Extreme. And we are in a swing for the fences type science and share price ownership. What JD reports is always the art of possible. He does not run the company. And his passion is in the right place. So unless you have something worthwhile to add to post how about stopping ? We know you hate JD and we know you are frustrated. Got it. If you have anything to add beyong that look forward to hearing from you. 
Bullboard Posts